I believe that with superior results from the P2B trial the stock will trade in low double digits at least. I think ONCS being able to turn nonresponders into responders + increase systemic immune response in a multibillion $ market, but trade in single digits, are two mutually exclusive events. Would not make sense for ONCS to trade on single digits in a couple of years if it does what we all think it has the potential to do IMO.
I also honestly believe ONCS will not be an independent company in 2-3 years. Big pharma need to replenish their pipeline and have a solid footing in where future growth lies to stay competitive and justify their share price. One way to do that is thru acquiring companies like Oncosec. And Oncosec is not a one trick pony and that makes them even more attractive. Hence I see no problem for a big pharma like Merck dropping a few billion dollars premium to acquire ONCS. Oncosec's technology if proven successful with Keytruda can make Merck the leader in cancer immunotherapy for at least the next decade or two. I therefore see no unrealism in a $20 pps. Very likely IMO that we don't grow to that price over time but get there overnight due to a BO offer.
News 
Market Data 
Discover 
